{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:30:46Z","timestamp":1790947846714,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["FP7-IDEAS-ERC-322856"],"award-info":[{"award-number":["FP7-IDEAS-ERC-322856"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-RHUS-0001"],"award-info":[{"award-number":["ANR-16-RHUS-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00125-020-05200-w","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T06:32:31Z","timestamp":1593585151000},"page":"1808-1821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I\/II randomised, double-blind, placebo-controlled, dose-finding study"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-6203","authenticated-orcid":false,"given":"Michelle","family":"Rosenzwajg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Salet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tchitchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Carel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Beltrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Amouyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Hartemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Corbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Bibal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bougn\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu-Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-3422","authenticated-orcid":false,"given":"David","family":"Klatzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"issue":"4643","key":"5200_CR1","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.6367043","volume":"223","author":"CR Stiller","year":"1984","unstructured":"Stiller CR, Dupre J, Gent M et al (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223(4643):1362\u20131367","journal-title":"Science"},{"issue":"11","key":"5200_CR2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/diab.37.11.1574","volume":"37","author":"The Canadian-European Randomized Control Trial Group","year":"1988","unstructured":"The Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37(11):1574\u20131582","journal-title":"Diabetes"},{"issue":"3","key":"5200_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00592-010-0188-2","volume":"47","author":"DO Sobel","year":"2010","unstructured":"Sobel DO, Henzke A, Abbassi V (2010) Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 47(3):243\u2013250. https:\/\/doi.org\/10.1007\/s00592-010-0188-2","journal-title":"Acta Diabetol"},{"key":"5200_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM198803173181103","volume":"318","author":"PF Bougneres","year":"1988","unstructured":"Bougneres PF, Carel JC, Castano L et al (1988) Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318:663\u2013670. https:\/\/doi.org\/10.1056\/NEJM198803173181103","journal-title":"N Engl J Med"},{"issue":"1","key":"5200_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/db12-0562","volume":"62","author":"TP Staeva","year":"2013","unstructured":"Staeva TP, Chatenoud L, Insel R, Atkinson MA (2013) Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 62(1):9\u201317. https:\/\/doi.org\/10.2337\/db12-0562","journal-title":"Diabetes"},{"issue":"3","key":"5200_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.smim.2011.07.003","volume":"23","author":"AW Michels","year":"2011","unstructured":"Michels AW, Eisenbarth GS (2011) Immune intervention in type 1 diabetes. Semin Immunol 23(3):214\u2013219. https:\/\/doi.org\/10.1016\/j.smim.2011.07.003","journal-title":"Semin Immunol"},{"issue":"1","key":"5200_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ni.1818","volume":"11","author":"K Wing","year":"2010","unstructured":"Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11(1):7\u201313. https:\/\/doi.org\/10.1038\/ni.1818","journal-title":"Nat Immunol"},{"issue":"11","key":"5200_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20040139","volume":"199","author":"Q Tang","year":"2004","unstructured":"Tang Q, Henriksen KJ, Bi M et al (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199(11):1455\u20131465. https:\/\/doi.org\/10.1084\/jem.20040139","journal-title":"J Exp Med"},{"issue":"289","key":"5200_CR9","doi-asserted-by":"publisher","first-page":"289ra81","DOI":"10.1126\/scitranslmed.aaa3032","volume":"7","author":"M Akbarpour","year":"2015","unstructured":"Akbarpour M, Goudy KS, Cantore A et al (2015) Insulin B chain 9\u201323 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Sci Transl Med 7(289):289ra81. https:\/\/doi.org\/10.1126\/scitranslmed.aaa3032","journal-title":"Sci Transl Med"},{"issue":"11","key":"5200_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2018.148","volume":"17","author":"A Sharabi","year":"2018","unstructured":"Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC (2018) Regulatory T cells in the treatment of disease. Nat Rev Drug Discov 17(11):823\u2013844. https:\/\/doi.org\/10.1038\/nrd.2018.148","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"5200_CR11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc12-0038","volume":"35","author":"N Marek-Trzonkowska","year":"2012","unstructured":"Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A et al (2012) Administration of CD4+CD25highCD127\u2212 regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children. Diabetes Care 35(9):1817\u20131820. https:\/\/doi.org\/10.2337\/dc12-0038","journal-title":"Diabetes Care"},{"issue":"4","key":"5200_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA et al (2013) Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1(4):295\u2013305. https:\/\/doi.org\/10.1016\/S2213-8587(13)70113-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"5200_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11892-014-0553-6","volume":"14","author":"M Rosenzwajg","year":"2014","unstructured":"Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D (2014) Interleukin 2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep 14(12):553. https:\/\/doi.org\/10.1007\/s11892-014-0553-6","journal-title":"Curr Diab Rep"},{"issue":"5","key":"5200_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK (2015) The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 15(5):283\u2013294. https:\/\/doi.org\/10.1038\/nri3823","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5200_CR15","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu A, Snowhite I, Vendrame F et al (2015) Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64(6):2172\u20132183. https:\/\/doi.org\/10.2337\/db14-1322","journal-title":"Diabetes"},{"key":"5200_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R et al (2015) Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun 58:48\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2015.01.001","journal-title":"J Autoimmun"},{"issue":"19","key":"5200_CR17","doi-asserted-by":"publisher","first-page":"pii:99306","DOI":"10.1172\/jci.insight.99306","volume":"3","author":"E Seelig","year":"2018","unstructured":"Seelig E, Howlett J, Porter L et al (2018) The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. JCI Insight 3(19):pii:99306. https:\/\/doi.org\/10.1172\/jci.insight.99306","journal-title":"JCI Insight"},{"issue":"12","key":"5200_CR18","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA (2014) IL-2: the first effective immunotherapy for human cancer. J Immunol Baltim Md 1950 192(12):5451\u20135458. https:\/\/doi.org\/10.4049\/jimmunol.1490019","journal-title":"J Immunol Baltim Md 1950"},{"issue":"4","key":"5200_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","volume":"9","author":"JP Siegel","year":"1991","unstructured":"Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9(4):694\u2013704","journal-title":"J Clin Oncol"},{"issue":"22","key":"5200_CR20","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F et al (2011) Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365(22):2067\u20132077. https:\/\/doi.org\/10.1056\/NEJMoa1105143","journal-title":"N Engl J Med"},{"issue":"2","key":"5200_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2337\/db09-0694","volume":"59","author":"SA Long","year":"2010","unstructured":"Long SA, Cerosaletti K, Bollyky PL et al (2010) Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes 59(2):407\u2013415. https:\/\/doi.org\/10.2337\/db09-0694","journal-title":"Diabetes"},{"issue":"5","key":"5200_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","volume":"28","author":"Q Tang","year":"2008","unstructured":"Tang Q, Adams JY, Penaranda C et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5):687\u2013697. https:\/\/doi.org\/10.1016\/j.immuni.2008.03.016","journal-title":"Immunity"},{"key":"5200_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2337\/diabetes.51.3.638","volume":"51","author":"A Rabinovitch","year":"2002","unstructured":"Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R (2002) Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51:638\u2013645","journal-title":"Diabetes"},{"issue":"9","key":"5200_CR24","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.2337\/db12-0049","volume":"61","author":"SA Long","year":"2012","unstructured":"Long SA, Rieck M, Sanda S et al (2012) Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs \u03b2-cell function. Diabetes 61(9):2340\u20132348. https:\/\/doi.org\/10.2337\/db12-0049","journal-title":"Diabetes"},{"issue":"9","key":"5200_CR25","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.2337\/db13-0214","volume":"62","author":"A Baeyens","year":"2013","unstructured":"Baeyens A, Perol L, Fourcade G et al (2013) Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes 62(9):3120\u20133131. https:\/\/doi.org\/10.2337\/db13-0214","journal-title":"Diabetes"},{"issue":"15","key":"5200_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","volume":"376","author":"EJ Mayer-Davis","year":"2017","unstructured":"Mayer-Davis EJ, Lawrence JM, Dabelea D et al (2017) Incidence trends of type 1 and type 2 diabetes among youths, 2002\u20132012. N Engl J Med 376(15):1419\u20131429. https:\/\/doi.org\/10.1056\/NEJMoa1610187","journal-title":"N Engl J Med"},{"issue":"2","key":"5200_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P et al (2019) Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 78(2):209\u2013217. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214229","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"5200_CR28","doi-asserted-by":"publisher","first-page":"eaan2946","DOI":"10.1126\/sciimmunol.aan2946","volume":"2","author":"N Aghaeepour","year":"2017","unstructured":"Aghaeepour N, Ganio EA, Mcilwain D et al (2017) An immune clock of human pregnancy. Sci Transl Med 2(15):eaan2946. https:\/\/doi.org\/10.1126\/sciimmunol.aan2946","journal-title":"Sci Transl Med"},{"issue":"398","key":"5200_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/01621459.1987.10478478","volume":"82","author":"GE Noether","year":"1987","unstructured":"Noether GE (1987) Sample size determination for some common nonparametric tests. J Am Stat Assoc 82(398):645\u2013647. https:\/\/doi.org\/10.1080\/01621459.1987.10478478","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"5200_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/aos\/1176347963","volume":"19","author":"JH Friedman","year":"1991","unstructured":"Friedman JH (1991) Multivariate adaptive regression splines. Ann Stat 19(1):1\u201367. https:\/\/doi.org\/10.1214\/aos\/1176347963","journal-title":"Ann Stat"},{"issue":"1","key":"5200_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2337\/dc19-0803","volume":"43","author":"JRJ Inshaw","year":"2020","unstructured":"Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2020) Genetic variants predisposing most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic \u03b2-cells. Diabetes Care 43(1):169\u2013177. https:\/\/doi.org\/10.2337\/dc19-0803","journal-title":"Diabetes Care"},{"issue":"8","key":"5200_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biom9080355","volume":"9","author":"A Paradowska-Gorycka","year":"2019","unstructured":"Paradowska-Gorycka A, Stypinska B, Pawlik A et al (2019) KDR (VEGFR2) genetic variants and serum levels in patients with rheumatoid arthritis. Biomolecules 9(8):355. https:\/\/doi.org\/10.3390\/biom9080355","journal-title":"Biomolecules"},{"issue":"52","key":"5200_CR33","doi-asserted-by":"publisher","first-page":"e18606","DOI":"10.1097\/MD.0000000000018606","volume":"98","author":"Z Yang","year":"2019","unstructured":"Yang Z, Wang M, Yan T, Hu Z, Zhang H, Liu R (2019) Association between vascular endothelial growth factor receptor 2 rs11941492 C\/T polymorphism and Chinese Han patients in rheumatoid arthritis. Medicine (Baltimore) 98(52):e18606. https:\/\/doi.org\/10.1097\/MD.0000000000018606","journal-title":"Medicine (Baltimore)"},{"key":"5200_CR34","doi-asserted-by":"publisher","unstructured":"Okamoto M, Watanabe M, Inoue N, Ogawa K, Hidaka Y, Iwatani Y (2020) Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto\u2019s disease and the intractability of graves\u2019 disease, respectively. Endocr J. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0480","DOI":"10.1507\/endocrj.EJ19-0480"},{"issue":"3","key":"5200_CR35","first-page":"75","volume":"15","author":"E Snarski","year":"2010","unstructured":"Snarski E, Milczarczyk A, Franek E, Jedrzejczak W (2010) Potential role of immunoablation and hematopoietic cell transplantation in the treatment of early diabetes type 1. Ann Transplant 15(3):75\u201379","journal-title":"Ann Transplant"},{"issue":"5","key":"5200_CR36","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1182\/blood-2006-02-004747","volume":"108","author":"E Zorn","year":"2006","unstructured":"Zorn E, Nelson EA, Mohseni M et al (2006) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108(5):1571\u20131579. https:\/\/doi.org\/10.1182\/blood-2006-02-004747","journal-title":"Blood"},{"issue":"1","key":"5200_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10637-018-0606-9","volume":"37","author":"T Price-Troska","year":"2019","unstructured":"Price-Troska T, Yang Z-Z, Diller D et al (2019) Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. Investig New Drugs 37(1):9\u201316. https:\/\/doi.org\/10.1007\/s10637-018-0606-9","journal-title":"Investig New Drugs"},{"issue":"8","key":"5200_CR38","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","volume":"20","author":"AA Kennedy-Nasser","year":"2014","unstructured":"Kennedy-Nasser AA, Ku S, Castillo-Caro P et al (2014) Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 20(8):2215\u20132225. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3205","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5200_CR39","doi-asserted-by":"publisher","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","volume":"13","author":"JA Todd","year":"2016","unstructured":"Todd JA, Evangelou M, Cutler AJ et al (2016) Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med 13(10):e1002139. https:\/\/doi.org\/10.1371\/journal.pmed.1002139","journal-title":"PLoS Med"},{"issue":"8","key":"5200_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nri2134","volume":"7","author":"L Chatenoud","year":"2007","unstructured":"Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7(8):622\u2013632. https:\/\/doi.org\/10.1038\/nri2134","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"5200_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dc13-0626","volume":"37","author":"MD Pescovitz","year":"2014","unstructured":"Pescovitz MD, Greenbaum CJ, Bundy B et al (2014) B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37(2):453\u2013459. https:\/\/doi.org\/10.2337\/dc13-0626","journal-title":"Diabetes Care"},{"issue":"8499","key":"5200_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","volume":"2","author":"G Feutren","year":"1986","unstructured":"Feutren G, Papoz L, Assan R et al (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2(8499):119\u2013124","journal-title":"Lancet"},{"issue":"5","key":"5200_CR43","first-page":"1043","volume":"141","author":"AK Barlow","year":"1992","unstructured":"Barlow AK, Like AA (1992) Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB\/Wor rat. Am J Pathol 141(5):1043\u20131051","journal-title":"Am J Pathol"},{"issue":"7","key":"5200_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl J Med"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05200-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T01:52:43Z","timestamp":1625104363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05200-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5200"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05200-w","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}